Table III.
Scoring of 15-PGDH protein and mRNA levels and COX-2 protein levels in gastric cancer with or without LM and H. pylori infection.
| H. pylori-positive, n | H. pylori-negative, n | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Metastasis | Total | 15-PGDH protein | 15-PGDH mRNA | COX-2 +/− | Total | 15-PGDH protein | 15-PGDH mRNA | COX-2 +/− | P-valuea |
| With LM | 23 | 0.46±0.19 | 0.18±0.07 | 23/0 | 21 | 0.90±0.40 | 0.44±0.20 | 16/5 | <0.01 |
| Without LM | 10 | 1.12±0.50 | 0.56±0.23 | 8/2 | 12 | 1.78±0.80 | 1.02±0.45 | 7/5 | <0.05 |
| P-valueb | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | |||
a
Comparison between H. pylori-positive and -negative samples
b
comparison between with LM vs. without LM 15-hydroxy prostaglandin dehydrogenase; COX-2, cyclooxygenase-2; LM lymphatic metastasis; H. pylori, Helicobacter pylori.